Aktuellt
SENASTE
The main point is the confirmation of the statistically significant eGFR benefits and the reduction in proteinuria, as revealed earlier. We point to further support for a potentially positive disease-modifying effect by Tarpeyo (Nefecon) as suggested by several established biomarkers. The study results support our base case (SEK 295), which rests on the potency of a targeted locally acting immunosurpressing product that also reduces inflammation. We also point to the benefit of providing more detailed results ahead of the critical PDUFA date on 20 December 2023.
LÄS MER
